A Single Center, Open-label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Allogeneic Dopaminergic Neural Precursor Cell(iDAP) Injection in the Treatment of Parkinson's Disease
Overview
- Phase
- Early Phase 1
- Intervention
- Allogeneic dopaminergic neural precursor cell(iDAP)
- Conditions
- Parkinson Disease
- Sponsor
- Anhui Provincial Hospital
- Enrollment
- 12
- Primary Endpoint
- Incidence and severity of adverse events.
- Status
- Not Yet Recruiting
- Last Updated
- last year
Overview
Brief Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that iDAP has on Parkinson's disease (PD) patients.
Detailed Description
Parkinson's disease (PD) is a common neurodegenerative disease in the middle-aged and elderly. It is the "third killer" of the middle-aged and elderly after tumors and cardiovascular and cerebrovascular diseases. Its main clinical manifestations are resting tremor, reduced voluntary movement, muscle rigidity, postural reflex impairment, and autonomic dysfunction, which seriously affect patients' work ability and quality of life. It is estimated that nearly 100,000 people in China become new Parkinson's patients every year. Experts from the World Health Organization predict that the number of Parkinson's patients in China will reach 5 million in 2030, which will be more than half of the world's total. As the disease progresses, the symptoms of Parkinson's patients will become increasingly severe. The high prevalence and high disability rate of Parkinson's disease bring heavy burdens to individuals, families, and society.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ages between 45 and 75 years;
- •Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria;
- •Disease history 4-20 years;
- •Hoehn and Yahr Stage 2-4;
- •Stable dose of dopamine for more than 3 months;
- •Improvement of MDS-UPDRS part III;
Exclusion Criteria
- •Patients who have previously undergone brain surgery;
- •Past use of stem cell therapy or participation in stem cell clinical research;
- •Cognitive impairment;
- •History of mental disorders;
- •Patients with other serious systemic diseases;
- •Past or current metastatic malignant tumors.
Arms & Interventions
Low dose
MRI-guided bilateral stereotactic cell implantation
Intervention: Allogeneic dopaminergic neural precursor cell(iDAP)
High dose
MRI-guided bilateral stereotactic cell implantation
Intervention: Allogeneic dopaminergic neural precursor cell(iDAP)
Outcomes
Primary Outcomes
Incidence and severity of adverse events.
Time Frame: Within 24 months post-transplantation
Safety and tolerability
Secondary Outcomes
- Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III, in comparison with baseline values.(Within 24 months post-transplantation)
- Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part I,II,IV, in comparison with baseline values.(Within 24 months post-transplantation)
- Assessment of changes in Hoehn & Yahr scale in comparison with baseline values.(Within 24 months post-transplantation)
- Brain network connectivity patterns as demonstrated on positron emission tomography(PET) compared with baseline in the 'off' state.(Within 24 months post-transplantation)
- Brain DAT intake index as demonstrated on PET dopamine transporter(DAT) compared with baseline in the 'off' state.(Within 24 months post-transplantation)
- Patient L-dopa equivalent dose compared with baseline.(Within 24 months post-transplantation)
- Assessment of changes in Mini-mental State Examination (MMSE), Hamilton Depression Scale (HAMD)-17 and Hamilton Anxiety Scale (HAMA)-14 in comparison with baseline values.(Within 24 months post-transplantation)
- Assessment of changes in Activity of Daily Living Scale (ADL) in comparison with baseline values.(Within 24 months post-transplantation)